



- (51) **International Patent Classification:**
C07D 215/40 (2006.01) *A61K 31/47* (2006.01)
- (21) **International Application Number:**
PCT/US2015/063425
- (22) **International Filing Date:**
2 December 2015 (02.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/086,355 2 December 2014 (02.12.2014) US
- (71) **Applicant:** 60 DEGREES PHARMACEUTICALS, LLC [US/US]; 1025 Connecticut Avenue N.W., Washington, District of Columbia 20036 (US).
- (72) **Inventors; and**
- (71) **Applicants :** SMITH, Bryan L. [US/US]; 3316 Park View Road, Chevy Chase, Maryland 20815 (US). JONES, John Paul [US/US]; 2244 Dabney Road, Richmond, Virginia 23230 (US). SCHMUKLARSKY, Moshe [US/US]; 9401 Balfour Drive, Bethesda, Maryland 30814 (US). BUDDA, Balasubrahmanyam [US/US]; 2244 Dabney Road, Richmond, Virginia 23230 (US).
- (72) **Inventor:** DOW, Geoffrey S.; 1714 Hobart St., N.W., Washington, District of Columbia 20009 (US).
- (74) **Agent:** DUNSTON, Erin M.; Buchanan Ingersoll & Rooney PC, P.O. Box 1404, Alexandria, Virginia 22313-1404 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]



(54) **Title:** NOVEL REGIMENS OF TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAÏVE SUBJECTS

FIG. 7



(57) **Abstract:** Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of *Plasmodium*, during potential exposure of a species of *Plasmodium*, and after potential exposure of a species of *Plasmodium*. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic mal-

aria in malaria-naïve, G6PD-normal subjects.



— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*